Daily Digest

The Valve Wire

Friday, June 5, 2026

Executive Summary

The FDA cleared the first dedicated tricuspid surgical valve replacement, an Edwards device, on the same day Edwards reported sustained two-year EVOQUE transcatheter tricuspid replacement benefits, bracketing the tricuspid space at both surgical and transcatheter ends simultaneously. The more consequential signal for the AS field: a meta-analysis of 25 studies and 13,846 patients shows self-expanding valves deliver better hemodynamics but more pacemakers and paravalvular leak in small annuli, with the safety gap closing in extra-small annuli (<400 mm² or <23 mm). Both signals tighten the case for anatomy-driven device selection while confirming that the structural tricuspid market is now a two-front war.

A single-center Marseille series of 479 TAVI patients found next-day discharge feasible in 57% overall, with conduction disturbances driving 56% of failed early discharges.
A retrospective propensity-matched TriNetX analysis links perioperative GLP-1 RA use to 56% lower one-year mortality after SAVR (4.8% vs 10.4%; HR 0.44) in diabetic and obese patients.
A 3,313-patient propensity-matched TAVI cohort showed analgosedation associated with lower 30-day mortality and less renal replacement therapy than general anesthesia, with no difference in postprocedural pneumonia.
The ASE released formal M-TEER intraprocedural imaging guidelines standardizing 2D, biplane, and 3D views for echocardiographers directing the procedure.
CT-defined myosteatosis independently predicted MACE (HR 2.39) and mortality (HR 3.83) in 371 TAVR patients, compounding with low muscle mass to a HR of 5.06.

What to watch: The SCCT 2026 program in San Diego (July 9-12), where photon-counting CT, structural heart procedural planning beyond TAVR, and AI-CT pre-procedural workflows will define the next imaging-driven inflection point.

Aortic Valve (TAVR/TAVI)

Anatomy is reasserting itself over device class in small-annulus AS. The 25-study, 13,846-patient meta-analysis from Abdelrahman et al. confirms self-expanding valves give a 0.20 cm²/m² larger indexed EOA, a 4.1 mmHg lower mean gradient, and a 63% lower severe PPM rate, but at the cost of 63% more pacemakers and 2.26× more moderate-or-severe paravalvular leak. In the extra-small annulus subgroup (<400 mm² or <23 mm), the hemodynamic advantage holds while the PPI and PVL signals lose significance — a result that will shift practice in women and Asian populations. ACC/AHA 2020 still favors SAVR with root enlargement under 65, and ESC 2025 under 70, precisely because PPM and reintervention compound over a 15-20 year horizon; this meta-analysis does not resolve that concern. The Marseille fast-track data reinforce that conduction disturbances remain the rate-limiting step for early discharge — and self-expanding valves make that worse. A separate 3,313-patient propensity-matched analysis found analgosedation associated with lower 30-day mortality and less renal replacement than general anesthesia, though the observational design cannot exclude institutional selection bias. CT-derived myosteatosis emerged as an independent predictor of post-TAVR MACE and mortality, with the worst outcomes in patients carrying both myosteatosis and low muscle mass (MACE HR 5.06). Sarcopenia screening belongs in standard pre-TAVR workup.

Mitral Valve (MitraClip, PASCAL, TMVR)

The new ASE M-TEER intraprocedural imaging recommendations codify 2D, biplane, 3D volume, and MPR formats at each procedural step, addressing variable-expertise directly as case volumes outpace operator training. The rate-limiting step for TEER is no longer evidence — ESC 2025 rates TEER Class I and ACC/AHA 2020 Class IIa for ventricular SMR — but consistent execution at scale. A JACC Case Reports series this week captures the maturing and complicating TMVR landscape: an acute M3 thrombosis rescued by valve-in-valve, a rapid hemodynamic collapse from iatrogenic ASD post-M-TEER, and a single-session pulsed-field AF ablation plus MitraClip plus Watchman triple procedure. The triple-therapy case is the canary: as ESC 2025 formally defines atrial functional MR as a distinct entity with its own management pathway, the combined LAAC+ablation+TEER approach will accelerate — but Cox-maze IV with concomitant MV repair still owns the durability data for surgical candidates. A separate registry comparison reported TEER for atrial functional MR reduced mortality and HF hospitalization vs medical therapy (HR 0.65) in OCEAN-Mitral/REVEAL-AFMR — non-randomized and hypothesis-generating, but the first outcome signal for this newly defined phenotype.

Tricuspid Valve (TriClip, TTVR)

[NOTABLE] The tricuspid space took its biggest commercial step in a decade. FDA cleared the first dedicated tricuspid surgical valve replacement, an Edwards device that — per Medical Design & Outsourcing — reportedly involves a modification of an existing platform. The clearance arrives the same week Edwards announced sustained two-year EVOQUE benefits from the TRISCEND II pivotal — a commercial pincer movement that positions Edwards on both sides of the surgical-vs-transcatheter line. ESC 2025 upgraded transcatheter TV treatment to Class IIa LOE A for high-risk symptomatic severe TR; ACC/AHA 2020 did not address transcatheter tricuspid therapy at all. The surgical clearance fills a real gap — no purpose-built tricuspid surgical valve existed before — and directly serves ESC's expanded Class I and IIa surgical recommendations for primary and secondary TR, which will drive volume toward earlier, lower-risk referrals. A separate TTVR case in a post-LVAD patient with torrential secondary TR and refractory RV failure shows the frontier extending into populations explicitly excluded from TRISCEND II. Real-world STS/ACC TVT registry data confirm 98.4% device success and 3.1% 30-day mortality with EVOQUE, consistent with pivotal trial results.

Surgical vs. Transcatheter Comparisons

The day's most provocative comparator is not a head-to-head trial but a SAVR-side metabolic signal. The TriNetX propensity-matched analysis of 1,984 matched pairs found perioperative GLP-1 receptor agonist use associated with a 56% reduction in 1-year mortality after SAVR (4.8% vs 10.4%; HR 0.44; 95% CI 0.34-0.56), with parallel reductions in AKI (HR 0.65), MI (HR 0.57), heart failure (HR 0.68), and AF (HR 0.69). The design is retrospective and observational; residual confounding by indication is plausible — patients prescribed GLP-1 RAs may be more engaged with care overall — but landmark analysis preserved the mortality, HF, and AKI signals, and falsification outcomes were null. If a TAVI-side analysis corroborates this signal, the modality choice in obese or diabetic patients under 70 may turn on access to optimized GLP-1 therapy rather than procedural risk alone. Neither ACC/AHA 2020 nor ESC 2025 incorporates metabolic comedication into the modality-selection algorithm. That will need to change.

Preprint Highlights

Beyond the SAVR-GLP-1 preprint, a bioRxiv mechanistic study of 70 patients demonstrated that severe AS drives epigenomic reprogramming of circulating T cells, with an 18-CpG methylation risk score discriminating AS from controls (AUC 0.89) and tracking hemodynamic severity. A separate IMM-AGE preprint showed baseline immune aging independently predicted one-year mortality and early maladaptive cardiac remodeling after TAVR. Both are early signals with no clinical application yet, but the direction is consistent: the next layer of TAVR risk stratification is biological, not anatomical or hemodynamic.

Device & Technology

Two ViV-TAVR case reports illustrate the durability problem the field cannot wish away. Two Perceval degeneration cases describe delivery system entrapment in the supra-annular nitinol ring and a successful antegrade transseptal bailout — a reminder that surgical bioprosthesis choice today dictates ViV feasibility in 8-12 years. ESC 2025 lifetime management thinking applies equally to surgical valves: the index implant pre-decides the reintervention pathway. Meanwhile, the Cardiovascular Business roundup from TAVR conference coverage reinforced that implant depth and antiplatelet strategy (SAPT vs DAPT) remain unsettled despite a decade of registry data.

Regulatory & Policy

The FDA tricuspid surgical valve clearance is the marquee regulatory event of the week. No new TAVR or M-TEER labeling changes were reported today.

Industry & Market

Edwards delivered the day's news flow — FDA clearance plus durable EVOQUE two-year data — and traders responded with a +1.69% session in EW. AlphaStreet's structural-heart-growth-story framing matters here: the market has been treating EW as a TAVR-saturation play, but simultaneous capture of the surgical and transcatheter tricuspid markets, plus PASCAL traction, is the multi-modality story that reframes the thesis. TD Cowen raised its EW target to $104 citing exactly this dynamic.

Financial Analysis

The trading session masked a structural divergence. Edwards finished within $0.31 of its 52-week and 6-month high on a tricuspid double-header, while Medtronic (+5.11%) and Abbott (+4.36%) staged outsized one-day rallies despite still sitting 18-27% below their 6-month highs. Boston Scientific (+2.43%) remains down ~50% from its 6-month peak. Structural heart device manufacturers are being repriced as macro names — anesthesia and sedation cost pressure, hospital capital budgets, Medicare reimbursement uncertainty — and the day's bounce in MDT/ABT/BSX looks more like a rate-driven sector rotation than a clinical re-rating. Edwards, by contrast, is being rewarded for delivering an actual catalyst. Whether the EVOQUE two-year durability data and the surgical tricuspid clearance translate into 2H 2026 revenue beats is where the structural-heart-growth narrative will be tested.

Valve Industry Stocks

6-Month Valve Industry Stock Performance

Edwards Lifesciences (EW)

Close: $87.45, +1.69% (+$1.45); 6-month: +1.46%; 52-week range $72.30-$89.14 (at high)
Market cap $50.4B; trailing P/E 47.27; forward P/E 25.97; beta 0.87
Analyst target $96.92 (26 analysts, range $84-$110); consensus Buy
Next earnings 2026-07-23: EPS est $0.74, revenue est $1.70B
Twin catalysts today — FDA clearance of the first dedicated tricuspid surgical valve and EVOQUE two-year durability data — push EW within $0.31 of its 52-week high. TD Cowen lifted target to $104. The thesis crystallizing in the sell-side: Edwards is no longer a TAVR-saturation story; it owns both sides of the tricuspid market.

Medtronic (MDT)

Close: $81.93, +5.11% (+$3.98); 6-month: -17.91%; 52-week range $73.31-$106.33
Market cap $105.2B; trailing P/E 21.97; forward P/E 12.71; beta 0.60
Analyst target $103.15 (26 analysts, range $80-$121); consensus Buy
Next earnings 2026-08-18: EPS est $1.39, revenue est $9.49B
Outsized one-day rally off recent lows, but structurally still well below 6-month highs. Evolut self-expanding TAVR continues to be the franchise; the small-annulus meta-analysis published today is favorable for SEV hemodynamics but reinforces the pacemaker liability.

Abbott (ABT)

Close: $90.78, +4.36% (+$3.79); 6-month: -26.60%; 52-week range $81.97-$139.06
Market cap $158.1B; trailing P/E 25.43; forward P/E 14.98; beta 0.62
Analyst target $117.29 (24 analysts, range $92-$135); consensus Buy
Next earnings 2026-07-16: EPS est $1.28, revenue est $12.53B
TriClip and Navitor remain the structural heart focus. The Edwards EVOQUE durability disclosure raises the bar for any TriClip-Navitor head-to-head data Abbott brings to TCT.

Boston Scientific (BSX)

Close: $48.85, +2.43% (+$1.16); 6-month: -49.91%; 52-week range $47.17-$109.50 (near low)
Market cap $72.6B; trailing P/E 20.44; forward P/E 13.10; beta 0.56
Analyst target $78.87 (30 analysts, range $55-$106); consensus Strong Buy
Next earnings 2026-07-29: EPS est $0.83, revenue est $5.38B
The steepest 6-month drawdown in the group. ACURATE neo2 commercial trajectory and Watchman+ comp pressure are weighing. The triple-therapy case report (TEER + LAAC + PFA) is incrementally bullish for Watchman pull-through.

Anteris Technologies (AVR.AX)

Close: A$13.80, +15.10% (+$1.81); 6-month: +111.01%; 52-week range A$4.68-$13.85 (at high)
Market cap A$1.3B; forward P/E -6.33 (pre-revenue); beta 0.73
Analyst target A$13.00 (1 analyst); no formal consensus
Pre-commercial DurAVR balloon-expandable platform doubled over 6 months on early clinical signal momentum. A reminder that small-cap structural heart names move on data, not earnings.

Structural heart stocks are bifurcating into catalyst-rewarded (EW, AVR.AX) and rate-and-rotation-driven (MDT, ABT, BSX). The Edwards EVOQUE plus tricuspid surgical clearance combination is the dual-modality moat the sell side has been waiting to see, and it explains the asymmetric reaction today.

Clinical Trial Updates

Aortic / Multi-valve:

NCT07626567 — HVU-NEURO: Prospective Neuropsychological Evaluation of the Implementation of a Heart Valve Unit. Status: Not Yet Recruiting. N/A phase, enrollment target 500. Sponsor: Heart and Brain Research Group, Germany. Last updated 2026-06-04. A first-of-its-kind effort to systematically measure neurocognitive outcomes following Heart Valve Unit care pathways, addressing a long-standing gap: the field tracks 30-day stroke but rarely tracks subclinical cognitive decline.

No status changes in REPAIR-MR, PRIMARY, EARLY TAVR, TRILUMINATE, CLASP TR, APOLLO, TRISCEND II, COAPT extension, or PARTNER follow-ups today. The next data drop to watch is the PRIMARY trial (TEER vs surgery in primary MR over 60), where ESC 2025's Class I upgrade for asymptomatic primary MR with risk factors sets the comparator bar high.

Social & Conference Highlights

The SCCT 2026 program (July 9-12, San Diego) previewed by chair Ronen Rubinshtein puts plaque imaging, AI-CCTA, photon-counting CT, and structural heart procedural planning beyond TAVR at the center. Former FDA commissioner Robert Califf delivers the keynote. The expansion of CT-based planning into mitral, tricuspid, and pulmonary intervention is the operational counterpart to the device approvals tracked week-to-week.

Next: TRISCEND II three-year data, ongoing PRIMARY enrollment milestones, and whether competitive transcatheter tricuspid platforms can match EVOQUE's two-year durability narrative ahead of TCT 2026.

← June 4, 2026